Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, S. (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y.H. (Experimental Therapeutics Group) ; Gris-Oliver, A. (Experimental Therapeutics Group) ; Bonache, S. (Oncogenetics Group) ; Morancho, B. (Vall d'Hebron Institut d'Oncologia) ; Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U.M. (Cancer Research UK. Cambridge Institute) ; Jones, G.N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzman, M. (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, J. (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratú, G. (Cancer Genomics Group) ; Mancuso, F. (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W.J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital de la Vall d'Hebron) ; Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J.C. (AstraZeneca (USA)) ; Caldas, C. (Cambridge University. NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre (UK)) ; Baselga Torres, Josep, 1959-, (Memorial Sloan Kettering Cancer Center (USA)) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Jonkers, J. (Cancer Genomics Group) ; Díez, Orland (Hospital Vall d'Hebron) ; O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of Oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  
2.
39 p, 4.7 MB mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer / Zabala Letona, Amaia (CIBERONC) ; Arruabarrena Aristorena, Amaia (CIC bioGUNE) ; Martín Martín, Natalia (CIBERONC) ; Fernández Ruiz, Sonia (CIBERONC) ; Sutherland, James D. (CIC bioGUNE) ; Clasquin, Michelle (AGIOS Pharmaceuticals) ; Tomás Cortázar, Julen (CIC bioGUNE) ; Jiménez, José (Hospital Universitari Vall d'Hebron) ; Torres Ramírez, Inés Ma. de (Hospital Universitari Vall d'Hebron) ; Quang, Phong (AGIOS Pharmaceuticals) ; Ximénez Embun, Pilar (Spanish National Cancer Research Centre) ; Bago, Ruzica (MRC Protein Phosphorylation and Ubiquitylation Unit) ; Ugalde Olano, Aitziber (Basurto University Hospital) ; Loizaga Iriarte, Ana (Basurto University Hospital) ; Lacasa Viscasillas, Isabel (Basurto University Hospital) ; Unda, Miguel (Basurto University Hospital) ; Torrano, Verónica (CIBERONC) ; Cabrera, Diana (CIC bioGUNE) ; van Liempd, Sebastiaan M. (CIC bioGUNE) ; Cendon, Ylenia (Universidad Autónoma de Madrid) ; Castro, Elena (Spanish National Cancer Research Centre) ; Murray, Stuart (AGIOS Pharmaceuticals) ; Revandkar, Ajinkya (University of Lausanne) ; Alimonti, Andrea (University of Lausanne) ; Zhang, Yinan (Harvard School of Public Health) ; Barnett, Amelia (AGIOS Pharmaceuticals) ; Lein, Gina (AGIOS Pharmaceuticals) ; Pirman, David (AGIOS Pharmaceuticals) ; Cortázar, Ana R. (CIC bioGUNE) ; Arreal, Leire (CIC bioGUNE) ; Prudkin, Ludmila (Hospital Universitari Vall d'Hebron) ; Astobiza, Ianire (CIC bioGUNE) ; Valcárcel Jiménez, Lorea (CIC bioGUNE) ; Zúñiga García, Patricia (CIC bioGUNE) ; Fernández Domínguez, Itziar (CIC bioGUNE) ; Piva, Marco (CIC bioGUNE) ; Caro Maldonado, Alfredo (CIC bioGUNE) ; Sánchez Mosquera, Pilar (CIC bioGUNE) ; Castillo Martín, Mireia (Fundação Champalimaud) ; Serra, Violeta (Hospital Universitari Vall d'Hebron) ; Beraza, Naiara (CIC bioGUNE) ; Gentilella, Antonio (Catalan Institute of Oncology) ; Thomas, George (Catalan Institute of Oncology) ; Azkargorta, Mikel (Carlos III Networked Proteomics Platform) ; Elortza, Felix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Farràs, Rosa (Centro de Investigación Príncipe Felipe) ; Olmos, David (Hospitales Universitarios Virgen de la Victoria y Regional de Málaga) ; Efeyan, Alejo (Spanish National Cancer Research Centre) ; Anguita, Juan (Ikerbasque) ; Muñoz, Javier (Carlos III Networked Proteomics Platform) ; Falcón Pérez, Juan M. (Ikerbasque) ; Barrio, Rosa (CIC bioGUNE) ; Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ; Mato, José M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Martínez Chantar, Maria L. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Cordon Cardo, Carlos (Icahn School of Medicine at Mount Sinai) ; Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Marks, Kevin (AGIOS Pharmaceuticals) ; Baselga Torres, Josep, 1959-, (Memorial Sloan-Kettering Cancer Center) ; Tabernero Caturla, Josep (Hospital Universitari Vall d'Hebron) ; Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ; Manning, Brendan D. (Harvard School of Public Health) ; Marjon, Katya (AGIOS Pharmaceuticals) ; Carracedo, Arkaitz (University of the Basque Country) ; Universitat Autònoma de Barcelona
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. [...]
2017 - 10.1038/nature22964
Nature, Vol. 547 (July 2017) , p. 109-113  
3.
12 p, 2.5 MB Cancer network activity associated with therapeutic response and synergism / Serra-Musach, Jordi (Institut Català d'Oncologia (ICO)) ; Mateo, Francesca (Institut Català d'Oncologia (ICO)) ; Capdevila-Busquets, Eva (Institut de Recerca Biomèdica (IRB Barcelona)) ; de Garibay, Gorka Ruiz (Institut Català d'Oncologia (ICO)) ; Zhang, Xiaohu (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Guha, Raj (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Thomas, Craig J. (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Grueso, Judit (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Villanueva, Alberto (Institut Català d'Oncologia (ICO).) ; Jaeger, Samira (Institut de Recerca Biomèdica (IRB Barcelona)) ; Heyn, Holger (Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)) ; Vizoso, Miguel (Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)) ; Pérez, Hector (Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)) ; Cordero, Alex (Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)) ; Gonzalez-Suarez, Eva (Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)) ; Esteller, Manel (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Moreno-Bueno, Gema (Universidad Autónoma de Madrid. Departamento de Bioquímica) ; Tjärnberg, Andreas (Linköping University. Departament of Clinical and Experimental Medicine) ; Lázaro, Conxi (Institut Català d'Oncologia (ICO)) ; Serra, Violeta (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Arribas, Joaquín (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Benson, Mikael (Linköping University. Department of Clinical and Experimental Medicine) ; Gustafsson, Mika (Linköping University. Department of Clinical and Experimental Medicine) ; Ferrer, Marc (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Aloy, Patrick (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Pujana, Miquel Àngel (Institut Català d'Oncologia (ICO))
Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer cell activity may support a comprehensive mechanistic understanding of therapy efficacy. [...]
2016 - 10.1186/s13073-016-0340-x
Genome Medicine, Vol. 8 (August 2016) , ART. 88  

Vea también: autores con nombres similares
1 Serra, Víctor
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.